Last reviewed · How we verify
NCT05754125: DiEx
In Vivo and in Vitro Anabolic Potential of Essential Amino Acids Following Resistance Exercise
NA trial testing Di-Leucine Supplement in Interventional in 12 participants. Status unknown.
30 July 2023
Quick facts
| Lead sponsor | University of Toronto |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | triple |
| Primary purpose | treatment |
| Enrollment | 12 |
| Start date | 21 January 2023 |
| Primary completion | 30 July 2023 |
| Estimated completion | 30 January 2024 |
| Sites | 1 location across Canada |
Drugs / interventions tested
- Di-Leucine Supplement
- BCAA Supplement
- Collagen Supplement
Conditions studied
- Interventional — all drugs for Interventional →
Sponsor
University of Toronto
Who can join
Adults 18 to 35, any sex, with Interventional. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study seeks to investigate the anabolic potential of a dileucine-enriched essential amino acid (EAA) formulation compared with a branched chain amino acid (BCAA) alternative and a collagen beverage on muscle protein anabolism and catabolism following a bout of resistance exercise training. To do this, investigators will employ a novel 'breath test' method developed in our laboratory as well as blood and urine sampling. The results of this study will allow us to better understand the anabolic potential of dileucine which could have implications for people engaging in regular resistance training (such as athletes) as well as people that need to preserve muscle mass (older people who are susceptible to anabolic resistance and sarcopenia, or muscle wasting).
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Dileucine-supplemented essential amino acids support whole-body anabolism after resistance exercise and serum-stimulated cell-based anabolism.
Aguilera JA, Tinline-Goodfellow CT, Lees MJ, Kortebi I, et al · · 2025 · PMID 41321015 · DOI 10.1080/15502783.2025.2590090
Verify or expand the search:
- PubMed search for NCT05754125
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other University of Toronto trials
Trials by the same sponsor.
- NCT07184255 — Animated Video Education for Retinal Surgery · NA · not yet recruiting
- NCT07259434 — Time Restricted Eating in Survivors Trial 2.0 · NA · not yet recruiting
- NCT07486050 — The Impact of Social Worker Referrals on Diabetes and Loneliness · NA · active not recruiting
- NCT07268729 — Investigation of Pathogenic Gut Microbiota Patterns in Anxiety, Depression and Panic Disorders · not yet recruiting
- NCT07317921 — Validating IAAO for Muscle Outcomes · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05754125 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Toronto
- Last refreshed: 9 November 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05754125.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing